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CROSS-PRESENTATION IS A SOURCE OF TUMOR ANTIGENS FOR 
MULTIPLE MYELOMA IMMUNOTHERAPY 
 
Alexander A. Perakis, B.A. 
Advisory Professors: Gheath Al-Atrash, D.O., Ph.D., Jeffrey J. Molldrem, MD. 
 
Cross-presentation is an essential bridge between the innate and adaptive 
arms of the immune system where antigen presenting cells (APCs) prime 
cytotoxic T cell responses. We have recently identified cross-presentation as a 
mechanism by which solid tumors present exogenous antigens. We therefore 
hypothesized that multiple myeloma would be capable of cross-presentation as 
these cells are derived from B cells, known APCs. We explored the capacity of 
multiple myeloma to cross-present PR1, a human leukocyte antigen (HLA)-A2 
nonameric peptide that is derived from neutrophil elastase (NE) and proteinase 3 
(P3), and the ability to treat multiple myeloma using PR1-targeting 
immunotherapies. Here we demonstrate that multiple myeloma cells lack 
endogenous NE and P3 expression, possess the ability to take up exogenous NE 
and P3 and cross-present PR1. This process employs the cytosolic antigen 
presentation machinery including the proteasome, Golgi, and TAP. Subsequent 
PR1 cross-presentation renders multiple myeloma cells susceptible to PR1-CTL 
and anti-PR1/HLA-A2 antibody, both in vitro and in vivo. To our knowledge, this 
is the first report of multiple myeloma cross-presenting tumor antigens. 
 ix 
Collectively, our data demonstrate that PR1 is a novel tumor antigen in multiple 
myeloma and can be effectively targeted using PR1-targeting immunotherapies. 
Our study suggests that the multiple myeloma antigen repertoire is much larger 
than previously appreciated, and that there is a new catalogue of potential 
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Chapter 1: Introduction 
1.1 The biology of multiple myeloma  
 
The evolution of multiple myeloma 
 Multiple myeloma is characterized by the proliferation of clonal plasma 
cells in the bone marrow. Normal plasma cells are terminally differentiated B 
cells, dedicated to the production and secretion of antibodies integral to the 
humoral response.1 Throughout B cell development, these cells undergo frequent 
error-prone genetic processes, such as VDJ recombination, somatic 
hypermutation, and Ig heavy chain (IgH) class switching, in order to generate 
high avidity antibodies. These genetic modification events are prime 
opportunities for malignant transformation to occur which can lead to the 
development of multiple myeloma.1,2  
 
Multiple myeloma develops from unique multi-step precursor stages where 
aberrant plasma cells become increasingly malignant. The first stage, 
monoclonal gammopathy of undetermined significance (MGUS) is asymptomatic 
and characterized by the presence of serum M-protein, less than 10% clonal 
plasma cells residing in the bone marrow and absence of end organ damage that 
is characterized by serum calcium, renal insufficiency, anemia, lytic bone lesions-
CRAB criteria.3 While not all cases of MGUS progress to multiple myeloma 
(approximately 1% increase per year), it can be appreciated that multiple 
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myeloma is frequently preceded by MGUS.4,5 Smoldering multiple myeloma 
(SMM) is characterized by more than 10% of clonal plasma cells residing in the 
bone marrow with absence of CRAB freatures.3 The disease progresses to 
multiple myeloma when CRAB features are manifested. Occasionally, multiple 
myeloma can progress to plasma cell leukemia, the most malignant form of the 
disease. Plasma cell leukemia exists when malignant plasma cells become 
independent of survival signals from the bone marrow microenvironment and are 
able to invade the peripheral blood and other organs.1 The stepwise process 
evolution from MGUS to SMM to multiple myeloma is orchestrated through 
multiple mechanisms involving DNA damaging events, reorganization of the bone 
marrow (BM) microenvironment, and escaping immune surveillance. This 
multifocal etiology of multiple myeloma is complex. While this project focuses on 
the interaction between the immune system and multiple myeloma, the 




The transformation of normal plasma cells into multiple myeloma involves 
the acquisition of several different genetic abnormalities. Genetic drivers of 
multiple myeloma are often classified into primary and secondary events. Primary 
events involve large-scale genetic changes that include immunoglobulin heavy 
chain (IgH) translocations, hyperdiploidy, and cyclin D overexpression.1,3 
Secondary events involve mutations in common oncogenes such as NRAS, 
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KRA, BRAF, NF-κB pathway, p53, PTEN, and RB inactivation.3 While the genetic 
abnormalities that occur in multiple myeloma patients are heterogeneous, the 
initiating events follow a common theme involving gains of chromosomes (such 
as 5, 9, 15, 19) or IgH translocation events that result in oncogene expression 
being driven by a strong enhancer region of the immunoglobulin (Ig) genes.1 The 
overexpression of the initial oncogenes can promote the accumulation of 
subsequent mutations leading to the development of multiple myeloma.   
 
Bone marrow microenvironment reorganization 
Genetic sequencing studies have revealed little differences between 
MGUS and multiple myeloma patients, highlighting the importance of the BM 
microenvironment in the progression of multiple myeloma.6,7 The BM 
microenvironment is composed of an intricate network of cells (BM stromal cells, 
osteoblasts, osteoclasts, endothelial cells, lymphocytes, myeloid cells) which play 
integral roles in hematopoiesis. As mirrored in many other solid tumor types, the 
BM microenvironment becomes dysregulated and customized to promote 
myelomagenesis. The bone marrow reorganization is largely due to the effects of 
a master regulator cytokine, Interleukin-6 (IL-6). 
 
Interactions between myeloma cells and BM stromal cells can lead to the 
secretion of IL-6 via the NF-κB pathway. IL-6 also influences multiple signaling 
axes (PI3K/Akt, JAK/Stat, NF-κB, Wnt), all of which become dysregulated to 
support the growth, survival and drug resistance of multiple myeloma.8,9 One of 
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the hallmark features of the BM microenvironment transformation mediated by 
multiple myeloma is the imbalance between osteoclasts and osteoblasts. 
Osteoclast activation leads to osteolysis and reduced osteoblast-mediated bone 
formation.9,10 
 
Solo, IL-6 also functions as a potent growth, survival and drug resistance 
factor and adversely affects the immune cells of the BM microenvironment 
leading to an immunosuppressive milieu.8 The potency of IL-6 in 
myelomagenesis is highlighted by the observations that when inhibited (via anti-
IL-6 antibodies) multiple myeloma cell proliferation decreased and cells were re-
sensitized to anti-myeloma drugs, dexamethasone and bortezomib.11 However, 
promising patient outcomes have yet to be observed in clinical trials targeting IL-




 Transformation of the immune microenvironment is critical to myeloma 
pathogenesis. Key components of the immune microenvironment consist of 
dendritic cells (DC), T cells, and myeloid derived suppressor cells (MDSC). 
Changes are found in each cell type, which contributes to the establishment of an 
immunosuppressive environment for multiple myeloma survival.  
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DCs have defective antigen presentation abilities in the context of multiple 
myeloma. This critical process is integral to the stimulation of cytotoxic T cell 
lymphocytes (CTL). There is a paucity of DCs observed in myeloma patients and 
furthermore, mature DCs in myeloma patients show reduced expression of co-
stimulatory molecules (CD40 and CD80) and lower expression of HLA-DR.13 
 
 Due to the plasticity of CD4 T cell development, a process heavily 
influenced by cytokines, the balance of T cell subsets in multiple myeloma is 
perturbed. The abundance of IL-4 and IL-10 in the BM microenvironment skews 
T cell development towards a Th2 phenotype rather than a Th1 phenotype, 
therefore favoring immune suppression.14 The role of T-regulatory cells (T-reg) is 
less understood in the context of myeloma due to the compartment they are 
analyzed from (peripheral blood vs. bone marrow) and the methods used for 
analysis (phenotypic vs functional). Some groups have demonstrated an 
abundance of T-regs while others have shown low T-reg percentages in the 
myeloma BM.13,14 However, it is well appreciated that the myeloma-derived T-
regs are dysfunctional and have profound differences compared to their health 
counterparts. Due to the effects of IL-6, the balance between Th1, Th17 and T-
reg cells heavily favors the Th17 phenotype. Th17 cells in turn produce IL-17, 
which has been shown to promote multiple myeloma cell growth, suppress T cell 
anti-tumor activities, and contribute to osteolytic bone disease.13,14 
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 Additionally, MDSCs contribute to defective T cell mediated immunity. 
Studies have shown MDSC populations to be elevated in multiple myeloma 
patients compared to healthy controls.13,15 Additionally, these cells produce 
arginase-1 which directly promotes myeloma tumor growth as well as depletes 
the extracellular matrix of arginine, an important amino acid for T cell activity.13,14 
MDSC also aid in myelomagenesis by assisting in the promotion of osteolytic 
bone disease as these cells can function as osteoclast progenitors.14 Key studies 
have also shown that myeloma cells can induce the development of MDSCs from 
monocytes, establishing a feedback loop that promotes multiple myeloma 
progression.15  
 
The network between multiple myeloma and the BM microenvironment is 
critical when considering new treatment strategies of multiple myeloma. This 
project aims to highlight an important interaction between multiple myeloma and 
myeloid cells that can be harnessed for new immunotherapy opportunities.  
 
1.2 Immunotherapy for the treatment of multiple myeloma 
The immune system is heavily implicated in the pathogenesis of multiple 
myeloma, suggesting many opportunities for therapeutic intervention. This has 
led to the recently increased interest in applying immunotherapy for the treatment 




Proteasome inhibitors and Immune modulatory drugs  
 The introduction of proteasome inhibitors (PI) and immune modulatory 
drugs (IMIDs) has changed the landscape of myeloma therapy, improving patient 
survival and outcomes.16,17 Proteasome inhibitors (bortezomib, carfilzomib) target 
the proteasome and inhibit intracellular protein degradation, causing cell cycle 
arrest through the endoplasmic reticulum (ER) stress response and apoptosis 
through the activation the unfolded protein response and activation of caspse-8 
and 9.18,19 Bortezomib is a boronate PI that inhibits the β5 subunit of the 
proteasome and was the first PI to see clinical success for the treatment of 
myeloma. Now, next generation PIs, carfilzomib and ixazomib, are currently 
being investigated in clinical trials and show promise as more potent options to 
bortezomib.20 Since bortezomib affects the proteasome, a key component in 
antigen presentation, we further investigated how bortezomib affects the ability of 
multiple myeloma to cross-present antigens.  
 
IMiDs (thalidomide, lenalidomide, pomalidomide) have multiple 
mechanisms of action that include both augmenting the immune system and 
direct anti-myeloma activity. These mechanisms involve promoting the 
production of IL-2, interferon (INF) γ and other pro-inflammatory cytokines that 
activate T cells and natural killer (NK) cells.21 Lenalidomide has also been 
demonstrated to induce the expression of DC maturation markers to promote 
antigen presentation to T cells.22 Currently, lenalidomide, in combination with 
other myeloma therapies is one of the standard of care treatments for newly 
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diagnosed patients.23 In this present work, we sought to determine how 
lenalidomide could modulate cross-presentation by multiple myeloma. 
 
Allogeneic stem cell transplant  
 While multiple myeloma remains incurable with standard therapies, which 
include autologous stem cell transplant (auto-SCT), allogeneic stem cell 
transplant (allo-SCT) has remained the only curative option for patients. This 
treatment strategy relies on a potent conditioning chemotherapy regimen that 
ablates the patient's bone marrow, followed by the infusion of stem cells (and 
other cellular components) from an HLA-matched-healthy donor to achieve a 
graft vs. myeloma (GvM) effect. The difficulty and limitation of this therapy comes 
from its highly toxic side effects such as graft vs. host disease (GvHD), where 
donor-derived T cells mount an immune response that targets host normal 
tissues. Oftentimes, the benefits of GvM are outweighed by the toxicity of allo-
SCT, which includes the side effects of the conditioning regimen as well as 
GvHD. Additionally, multiple myeloma is more often diagnosed in elderly patients 
who are more susceptible to the side effects of the myeloablative conditioning 
regimens, limiting this therapy to younger and healthier patients.24,25 Therefore, 
there is an interest in identifying new immunotherapies, that offer a more targeted 





Targeting multiple myeloma antigens with immunotherapies 
 Currently the most promising immunotherapies used to treat multiple 
myeloma target myeloma-associated antigens. There are only a handful of 
myeloma-specific antigens, most commonly cancer testis antigens (MAGE-A3 
and NY-ESO-1). These targets are under current investigation in ongoing clinical 
trials.26 Most of the current immunotherapies target myeloma-associated 
antigens, proteins and antigens that are enriched on the surface of myeloma and 
plasma cells. The immunotherapy modalities currently under investigation are 
similar to the immunotherapies being used in other tumor settings such as 
monoclonal antibodies, chimeric antigen receptor T cells (CAR-T), bispecific T 
cell engagers (BiTE), and immune checkpoint inhibition.  
 
 To date, two monoclonal antibodies are clinically FDA approved for the 
treatment of multiple myeloma: daratumumab (targets CD38) and elotuzumab 
(targets SLAMF7). CD38 is highly expressed on plasma cells, NK cells, and 
myeloid cells. Daratumumab has multiple methods of activity including 
complement-dependent cytotoxicity (CDC), antibody-dependent cytotoxicity 
(ADCC) as well as Treg and MDSC-inhibition.27,28 Similarly elotuzumab also has 
ADCC activity and can activate NK cells as SLAMF7 is highly expressed on both 
plasma cells and NK cells.29 CAR-T cells are genetically engineered T cells that 
have the antigen recognition regions of a monoclonal antibody linked to the TCR 
domains and co-stimulatory domains, resulting in a T cell that can directly 
recognize an antigen of choice. CAR-T cells have been used in the setting of 
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multiple myeloma, targeting CD19 and B cell maturation antigen (BCMA). 
Additionally, CD19 has been targeted using BiTE and preclinical studies have 
investigated targeting CD38 and CD138.30 Immune checkpoint inhibition through 
the use of blocking antibodies is also under investigation in multiple myeloma. 
Program death-ligand 1 (PD-L1) expression is upregulated on myeloma cells in 
patients and its receptor, programmed cell death protein-1 (PD-1) expression is 
elevated on the T cells and NK cells.31  
 
While there are a number of multiple myeloma targets and different 
immunotherapeutic strategies under investigation, many of these aforementioned 
treatments have yielded promising but limited clinical results, mainly as they fail 
to fully eradicate the underling multiple myeloma. Thus, there is a continued need 
for further investigation into improving the current modalities and searching for 
novel immunotherapies.  
 
1.3 Antigen presentation and cross-presentation 
While the exact mechanisms of how multiple myeloma avoids immune 
destruction remain unclear, it is clear that CD8+ T cells fail to manage the 
outgrowth and expansion of multiple myeloma cells. A critical step in T cell 
activation occurs through the ability of both dendritic cells and tumor cells to 
present antigen. Moreover, downregulation of antigen presentation is a common 
strategy employed by tumor cells to avoid immune detection.32 Therefore, in this 
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present work we focused on investigating the biology of antigen presentation in 
multiple myeloma. 
 
Human leukocyte antigen system  
 Antigen presentation is the process by which antigens, usually proteins, 
are degraded intracellularly into small peptide fragments that are displayed on 
the cell surface in the context of human leukocyte antigen (HLA) class I and class 
II molecules for recognition by T cells. HLA class I is a heterodimer cell surface 
molecule that consists of a α-heavy chain which is encoded by the highly 
polymorphic HLA gene (HLA-A, -B, and -C) and β2-microglobulin, and presents 
antigens recognized by CD8+ T cells. HLA class II molecules (HLA-DM, -DP, -
DO, -DQ, -DR) are also heterodimers, but consist of a α-chain and β-chain-both 
of which are encoded by HLA genes and presents antigens to CD4+ T cells. The 
polymorphisms of the HLA genes allows for fine-tuning of the adaptive immune 
responses and plays a major role in hematopoietic and solid organ 
transplantation. The HLA-A2 haplotype has garnered interest due to having the 
highest frequency among the Caucasian population. Importantly, HLA class I 
downregulation does not appear to be a common immune escape mechanism in 
multiple myeloma, as it can be for other tumor types. However, Racanelli and 
colleagues have demonstrated that while antigen presentation in multiple 
myeloma cells is altered, many of the components of the antigen presentation 
machinery (APM) were upregulated in multiple myeloma patients.33 Additionally, 
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work from our group has suggested that HLA class I is abundantly expressed on 
the cell surface of multiple myeloma.33,34  
  
Antigen presentation pathway 
The mechanism by which HLA molecules present antigens to the immune 
system is accomplished through an organized, step-wise process known as the 
antigen presentation pathway (Figure 1). Classically, HLA class I molecules 
display antigens that are expressed endogenously in the cytosol. Intracellular 
proteins are first targeted for degradation by the proteasome, which facilitates the 
generation of small, 8-10 amino acid peptides that are favored for HLA class I 
binding. Unfolded, immature HLA class I heavy chain molecules reside in the ER 
and are stabilized by the chaperon protein-calnexin (CNX) before binding to β2-
microglobulin (β2M). Upon β2M binding, HLA molecules are stabilized and 
subsequently released from CNX. Next, HLA binds to the peptide-loading 
complex (PLC) consisting of calreticulin, tapasin and transporter associated with 
antigen processing protein 1 and 2 (TAP1/2).  
 
The peptides are transported from the cytosol into the ER via the TAP1/2 
protein where they interact with the PLC and HLA. The PLC orchestrates both 
peptide editing and binding to HLA to allow for proper binding to HLA. Once a 
high affinity peptide binds to the peptide groove of HLA, the HLA molecule is 
released from the PLC and shuttled through the ER to Golgi transport and 
displayed on the cell surface to interact with CD8+ T cells. While this pathway 
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facilitates endogenous peptide recognition, exogenous peptides can also be 
displayed to cytotoxic T cells via the cross-presentation pathway. 
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Figure 1: Overview of the antigen presentation pathway.  
 
 
Figure 1: Overview of the antigen presentation pathway. Unfolded HLA class 
I molecules reside in the ER, stabilized by calnexin. Upon β2M binding, HLA 
class I molecules bind to the peptide-loading complex composed of calreticulin, 
TAP1/2, and tapasin. Endogenous antigens are loaded onto HLA class I 
molecules after being processed by the proteasome in the cytoplasm. Antigens 
are then transported into the ER lumen via TAP1/2 where they bind to HLA class 
I. Upon binding a high affinity peptide, HLA class I molecules are then shuttled to 




 Cross-presentation is integral to the anti-tumor immune response as it 
allows DC priming of naïve CD8+ T cells against exogenous antigens. Much of 
how exogenous antigens are processed and cross-presented mirrors the 
pathway of how endogenous antigens are presented with a few notable unique 
characteristics.35  
 
The defined means by which peptides are initially transported from the 
microenvironment into the cytosol remains an area of active research. There are 
three popular models that describe cross-presentation. The first model is the 
cytosolic pathway model. In this model, the antigen is internalized in a 
phagosome through phagocytosis. In the phagosome, the antigen can be 
exported to the cytosol for proteasomal degradation. The processed antigen can 
then either be loaded onto HLA class I molecules in the ER (similar to classical 
antigen presentation) or re-imported into the phagosome which can contain its 
own PLC and HLA class I molecules.36-38 Alternatively, in the vacuolar model, 
internalized antigens are processed by phagosomal degradation and loaded onto 
HLA class I molecules in the phagosome.36 The peptide exchange model 
describes another possible mechanism of how exogenous peptides are imported 
into the cell. In this model, surface HLA class I molecules that have already 
bound peptide are recycled back into the phagosome where old peptides can 
exchange for newly generated exogenous peptides.37,38 HLA class I re-
internalization is facilitated through monoubiquitination of a conserved lysine 
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residue (tyrosine in mouse) in the cytosolic tail of the HLA class I molecule.37,39 
Importantly, the peptide exchange model offers a TAP-independent mechanism 
for exogenous peptide loading.  
 
Cross-presentation has previously been limited to hematopoietic cells, 
specifically professional antigen presenting cells (APC; notably DC, 
macrophages, and B cells). However, recent work from our group has 
demonstrated that solid tumor cells (breast cancer, melanoma, lung cancer) are 
capable of cross-presentation.40-44 In the case of multiple myeloma, we 
hypothesized multiple myeloma can cross-present antigen, due to their 
hematopoietic lineage.  
 
1.4 PR1 as an immunotherapeutic target 
 
Neutrophil elastase, proteinase 3, and PR1 
Neutrophil elastase (NE) and proteinase 3 (P3) are two myeloid azurophil 
granule specific serine proteases expressed by myeloid progenitor cells, 
polymorphonuclear leukocytes (PMNs) and monocytes. NE and P3 possess 
normal antimicrobial effects in the context of inflammation. These serine 
proteases reside in the azurophil granules; specialized lysosomes within the 
neutrophil, where pathogenic proteins are hydrolyzed. Additionally, NE can be 




PR1 (sequence: VLQELNVTV) is a nonameric HLA-A*0201 (HLA-A2) 
restricted peptide derived from NE (amino acids 168-176) and P3 (amino acids 
128-136).46 PR1 was originally discovered and characterized from acute myeloid 
leukemia (AML) and chronic myelogenous leukemia (CML). In these tumor 
settings, NE and P3 are aberrantly expressed, making PR1 an attractive tumor 
antigen for immunotherapy.41,46-48 While this would appear to limit PR1 as a 
therapeutic target to only hematologic malignancies that aberrantly express NE 
and P3, there is a preponderance of work from our group that suggests PR1 can 
be targeted in other tumor types via cross-presentation of NE and P3. Prior to 
this current work, our group has demonstrated that non-myeloid tumor types 
(breast cancer, melanoma, lung cancer) can take up and internalize NE/P3 from 
neutrophils and cross-present PR1 in the context of HLA-A2.40-44 
 
PR1-targeting immunotherapies 
We first demonstrated the feasibility of targeting PR1 with immunotherapy in 
patients with relapsed/refractory AML, CML, and myelodysplastic syndrome 
using a PR1-peptide vaccine and demonstrated that vaccination can achieve 
objective clinical responses.49 We further developed a T-cell receptor (TCR)-like 
monoclonal antibody that recognizes the PR1/HLA-A2 complex (8F4 antibody). 
The 8F4 antibody is unique in that it recognizes the combined epitope of the 
PR1/HLA-A2 complex, mimicking the manner by which TCRs recognize 
peptide:HLA complexes. However, 8F4 retains the high binding affinity of an 
antibody (dissociation constant [KD] = 9.9nM).50,51 
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8F4 has shown broad anti-leukemia activity against AML cell lines, primary 
AML patient samples, and patient derived xenograft models. Specifically, our 
group has illustrated that 8F4 antibody can induce complement-dependent 
cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) against 
AML in vitro and specifically inhibits growth of AML progenitor cells.50 
Furthermore, we have also shown that 8F4 has anti-leukemia functionality 
against primary human AML cells in vivo by reducing the leukemia burden, 
extending survival, and inhibiting AML engraftment in human xenograft mouse 
models.52 Based on the success of this work 8F4 is currently being tested in an 
ongoing Phase I/II clinical trial.  
 
Based on the unique characteristics of multiple myeloma and its 
microenvironment, we hypothesize that multiple myeloma can take up NE and P3 
and subsequently cross-present the PR1 peptide on the cell surface, rendering 
multiple myeloma susceptible to PR1-targeting immunotherapies. This 
hypothesis is based on the observation that multiple myeloma is a malignant 
plasma cell, which originates from the B cell lineage (a known APC), suggesting 
these cells will be capable of cross-presentation. Additionally, the bone marrow 
microenvironment, where multiple myeloma homes to, is rich in myeloid 




Chapter 2: Materials and Methods 
 
The following chapter is based on my publication, used with permission granted 
by AACR Journals.  
 
Alatrash, G.1, Perakis, A.A.1, Kerros, C., Peters, H.L., Sukhumalchandra, P., 
Zhang, M., Jakher, H., Zope, M., Patenia, R., Sergeeva, A., Yi, S., Young, K.H., 
Philips, A.V., Cernosek, A.M., Garber, H.R., Qiao, N., Weng, J., St John, L.S., 
Lu, S., Clise-Dwyer, K., Mittendorf, E.A., Ma, Q. & Molldrem, J.J. Targeting the 
Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple 
Myeloma. Clin Cancer Res 24, 3386-3396 (2018). 
 
2.1 Cells and cell culture 
Arkansas (ARK), LP-1, ARP-1, IM-9, OPM-2, RPMI 8226 and U266 
multiple myeloma cell lines, U937 histiocytic leukemia cell line, T2 T/B cell 
hybridoma cell line, H2023 lung cancer cell line, and T-47D and MDA-MB-453 
breast cancer cell lines were all acquired from ATCC. All cell lines were cultured 
in RPMI 1640 media with 25 mmol/L HEPES + l-glutamine (Hyclone) and 
supplemented with 10% fetal bovine serum (Gemini Bio-Products), 100 U/mL 
penicillin, and 100 μg/mL streptomycin (Cellgro). All cell lines were cultured in 5% 
CO2 incubator at 37°C. All cell lines were thoroughly verified using short tandem 




Cell mRNA was purified from cell lines using RNA Stat 60 kit (TelTest) and 
cDNA was synthesized using Gene AMP RNA kit (Perkin Elmer). Amplification of 
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cDNA was performed using iCycler (Bio-Rad) using the following primer sets: NE 
forward primer 5′-CACGGAGGGGCAGAGACC-3′ and NE reverse primer 5′-
TATTGTGCCAGATGCTGGAG-3′; P3 forward primer 5’-
GACCCCACCATGGCTCAC-3’ and P3 reverse primer 5’-
ATGGGAAGGACAGACAGGAG-3’; actin forward primer 5’-
CCAGAGCAAGAGAGCTATCC-3’ and actin reverse primer 5’-
CTGTGGTGGTGAAGCTGTAG-3’.40,53 DNA was separated on 1.5% agarose gel 
and detected using GelDoc2000 (Bio-Rad). 
 
2.3 Western blotting 
Cell lysates were prepared for western blotting by resuspending cell 
pellets in lysis buffer (10 mM/L HEPES [pH 7.9], 10mM/L KCl, 0.1mM/L EGTA 
0.1mM/L EDTA, 1 mM/LDTT) containing proteases inhibitors (Thermo Fisher 
Scientific). Lysis reaction was performed for 30 minutes at 4°C. Protein 
concentrations were calculated using standard Bradford assay (Bio-Rad).  
Protein separated on 10% SDS gels (Bio-Rad) using electrophoresis under 
reducing conditions and transferred onto polyvinylidene fluoride membranes. 
Prior to immunoblotting, membranes were blocked with 5% milk solutions in 
0.05% TBS-Tween. Membranes were probed using antibodies against NE (Santa 
Cruz Biotechnology), P3 (NeoMarkers), actin (Millipore), GAPDH (Millipore), 
Calnexin, LMP2, LMP7, Tapasin (all Cell Signaling), TAP1 (Enzo Life Sciences), 
Pan-HLA (HC-10 hybridoma) and peroxidase-conjugated secondary antibodies 
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(Jackson ImmunoResearch). Chemiluminescence signal was measured on film 
(Kodak) and digitally using ChemiDoc Touch Imaging System (Bio-Rad).  
 
 
2.4 Antigen cross-presentation assay 
Cells were cultured with 10μg NE, P3 (Athens Research & Technology), 
EndoGrade ovalbumin (Ova; Hyglos) or irradiated PMNs or peripheral blood 
mononuclear cells (PBMCs; 1:1 ratio) at varying durations. Cells were 
permeabilized by washing in Perm/Wash buffer (BD Biosciences) and stained 
with fluorochrome-conjugated antibodies (Invitrogen) against P3 (Thermo 
Scientific) or NE (Santa Cruz Biotechnology). Cross-presentation of peptides was 
measured by staining with fluorescently conjugated anti-PR1/HLA-A2 antibody 
(8F4). Inhibition of cross-presentation was accomplished by treating cell cultures 
with the endoplasmic reticulum (ER) to Golgi anterograde inhibitor, brefeldin A 
(Sigma-Aldrich), or proteasome inhibitors, lactacystin (Sigma-Aldrich) or 
bortezomib (Millennium Pharmaceuticals). To determine the effect of IMiDs on 
cross-presentation, cell cultures were treated with lenalidomide (Celgene). 
 
2.5 Peptide-specific CTL generation 
 PR1-specific CTL were generated from HLA-A2 healthy donor PBMC by 
stimulating with PR1 peptide (Bio-synthesis Inc.) in vitro. PBMC from healthy 
donor leukapheresis were isolated using Histopaque 1077 gradient centrifugation 
(Sigma-Aldrich) and were co-cultured with PR1 (20 μg/mL)-pulsed T2 cells at 1:1 
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ratio in RPMI 1640 media supplemented with 10% human AB serum (Gemini 
Bio-Products). Cell cultures were restimulated with PR1-pulsed T2 cells and 20 
IU/mL of recombinant human IL-2 (Biosource International) on days 7, 14, and 
21. 
2.6 Cell-mediated cytotoxicity assay 
Target cells (1x 103 cells/mL) were fluorescently labeled with calcein-AM 
(Invitrogen) for 15 minutes at 37°C and then thoroughly washed with RPMI 1640 
to remove free calcein-AM. Target cells were co-cultured with peptide specific 
CTL at indicated effector-to-target (E:T) ratios for 4 hours at 37°C in 60 well 
Terasaki plates. Trypan blue was added to each well to stop the reaction. The 
fluorescence was measured on a CytoFluor II plate reader (Applied Biosystems). 
The percent cytotoxicity was calculated as follows:  
((1 − 𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑒𝑛𝑐𝑒-./01-213314-5/	– 𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑒𝑛𝑐𝑒819:.)/𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑒𝑛𝑐𝑒-./01-	.=5>1 −
𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑒𝑛𝑐𝑒819:.)) 	× 	100  
 
2.7 Complement-mediated cytotoxicity assay 
 U266 cells (1x 106 cells) were cultured with soluble NE or P3 for 24 hours 
and then labeled with calcein AM. U266 cells were resuspended in serum-free 
RPMI 1640 media and treated with anti-PR1/HLA-A2 antibody (8F4) or isotype 
control antibody for 10 minutes at 37°C. Standard rabbit complement (C’) 
(Cedarlane Labs) was added and cells were incubated for 60 minutes at 37°C. 
Fluorescence was measured and cytotoxicity was measured as described in 
section 2.6. 
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2.8 Staining for PR1-CTL in multiple myeloma patient samples 
Patient and HD peripheral blood (PB) samples and BM aspirates were 
collected after informed consent to participate in an MD Anderson Cancer Center 
institutional review board-approved study. PBMC were isolated using Histopaque 
1077 gradient centrifugation (Sigma-Aldrich). PBMC were stained using the 
following fluorescent antibodies: CD8 APC-H7 (BD), CD3 FITC (BD), PE-
conjugated PR1/HLA-A2-dextramer (Immudex) or tetramer (Baylor College of 
Medicine MHC Tetramer Core (Houston, TX) and the following pacific blue 
conjugated lineage antibodies: CD4 (BD), CD14 (BD), CD16 (BD) and CD19 
(Biolegend). Samples were fixed with 4% paraformaldehyde. Data were acquired 
on a Canto flow cytometer (BD Biosciences) and analyzed using FlowJo software 
(Tree Star). The frequency of PR1-CTL was determined as the percentage of live 
cells that were lineage-, CD3+, CD8+ and PR1-dextramer+ or tetramer+. 
Phenotype of PR1-CTL (PR1/HLA-A2-dextramer+) was investigated using CCR7 
PE-Cy7 (Biolegend) and CD45RA PerCP-Cy5.5 (Biolegend) staining, and was 
classified as central memory (CCR7+/CD45RA-), effector memory (CCR7-
/CD45RA-), naïve (CCR7+/CD45RA+) or terminally differentiated (CCR7-
/CD45RA+).  
 
2.9 Confocal staining and imaging 
Bone marrow smears and U266 cells were fixed with cold acetone and 
blocked with 5% normal mouse serum (Jackson ImmunoResearch). Fixed slides 
were washed with PBS and then double stained with Alexa-647 conjugated 8F4 
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antibody and Alexa-488 conjugated mouse anti-human HLA-A2 antibody 
(Serotec) or Alexa-488 conjugated rabbit anti-CD138 antibody (Bioss). Slides 
were stained with antibodies for 90 minutes at room temperature. After washing, 
ProLong Gold antifade reagent with DAPI (Invitrogen) was added. Confocal 
imaging was performed using Leica Microsystems SP2 SE confocal microscope 
with 10x/25 air, 63x/1.4 oil objectives. Leica LCS software (version 2.61) was 
used for image analysis. 
 
2.10 U266 myeloma xenograft animal model 
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) female mice were purchased from 
Jackson Laboratory and housed at MDACC following International Animal Care 
and Use Committee-approved protocol. Mice received sublethal irradiation 24 
hours prior to intravenous injection with 2x106 U266 cells 54. U266 engraftment 
and disease burden was measured by quantifying blood human IgE level by 
ELISA (Bethyl Laboratories). Mice were treated intravenously with 0.5 x 106 PR1-
CTL, irrelevant peptide (CG1, E75)-CTL or left untreated (PBS-treated) 14 days 
after U266 engraftment. Mice were treated intravenously with 8F4 antibody 
(10mg/kg) or IgG1 isotype control (Herceptin, 10mg/kg) three-times per week 
beginning on day 28 for a total of 10 injections.52 Mice that received bortezomib 
(Millennium Pharmaceuticals) or carfilzomib (Sellek Chemicals) received four 
weekly intravenous injections of the respective proteasome inhibitor (0.025 
mg/kg). Mice were sacrificed 35 days after CTL infusion or 3-4 days after last 
antibody treatment, and bone marrow was harvested, stained with mouse CD45, 
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human  (h) CD45, hCD138, and HLA-A2 fluorescently conjugated antibodies and 
then analyzed by flow cytometry. 
 
2.11 Annexin V apoptosis assay  
 U266 cells were co-cultured with irradiated PMN (1:3 ratio) for 24 hours 
prior to experimentation. The next day, U266 (2x105 per well) were seeded into a 
96-well plate and resuspended in fresh medium. U937-WT (U937-wild type) and 
U937-A2 (U937-HLA-A2 transduced) cells were used as negative and positive 
controls respectively. Cells were treated with either 8F4 alone (2 mg/mL), 
bortezomib alone (2.5 nM, Millennium Pharmaceuticals) or in combination 
overnight at 37°C. Cross-linking antibody Fab fragments were added to cells 
(Jackson ImmunoResearch) to facilitate 8F4 mediated apoptosis. Cells were then 
washed in PBS and intracellularly stained for Annexin V (BD Biosciences), 
propidium iodide (BD Biosciences), and anti-CD138 (Biolegend) to identify U266 
cells in a 96 well plate. Cells were analyzed on a LSR Fortessa (BD Biosciences) 
and FlowJo software (Tree Star). Apoptosis percentages were calculated by 
adding the Annexin V+ and Annexin V+PI+ gates. 
 
 
2.12 Statistical analysis  
 All statistical analyses were calculated using GraphPad Prism 6.0 and 7.0 




Chapter 3: Specific Aims 
 
Aim 1: Determine the extent of NE and P3 uptake and PR1 cross-
presentation by multiple myeloma  
 
Cross-presentation of extracellular proteins has been demonstrated in 
several other tumor types (breast cancer, melanoma, lung cancer).40-44 Since 
multiple myeloma differentiates from the B cell, a known APC, we hypothesize 
that multiple myeloma has the capability to take up NE and P3 and subsequently 
cross-present the PR1 peptide on the cell surface. Lack of endogenous transcript 
and protein expression of NE and P3 will be determined in multiple myeloma cell 
lines by RT-PCR and western blot analysis respectively.  The ability of multiple 
myeloma cell lines to take up NE and P3 from soluble and cellular sources will be 
determined using flow-based assays by staining for internalized NE and P3 
protein. Cross-presentation of PR1 by multiple myeloma will be measured by 
staining for PR1/HLA-A2 surface expression using the 8F4 antibody. 
 
Aim 2: Evaluate the susceptibility of multiple myeloma to PR1-targeting 
immunotherapies 
 
PR1-targeting immunotherapies have been utilized with great success for 
the treatment of myeloid malignancies.40,49,50,52,55-58 We hypothesize that cross-
presentation of PR1 will render multiple myeloma susceptible to 
immunotherapies targeting PR1. Susceptibility to PR1-targeting immunotherapies 
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will be investigated using PR1-specific CTL and 8F4 antibody. The HLA-A2+ 
U266 multiple myeloma cell line will be co-cultured with NE and P3 to facilitate 
cross-presentation of PR1 and will be co-cultured with PR1-CTL or 8F4 antibody. 
Cytotoxicity to PR1-targeting immunotherapies will be measured in vitro using 
calcein-AM cytotoxicity assays. The therapeutic ability of 8F4 antibody to 
eliminate human multiple myeloma in vivo will be investigated using a human 
multiple myeloma xenograft mouse model. Human U266 multiple myeloma cells 
will be transplanted into NSG mice. Mice will be treated with PR1-CTL or 8F4 
antibody. Bioluminescent imaging and ELISA will be used to measure disease 
progression and assess the therapeutic potential of 8F4 in multiple myeloma. 
Additionally, we will investigate how 8F4 can be integrated into standard of care 
therapies for multiple myeloma. Xenograft mice will be treated with 8F4 in 
combination with bortezomib, a standard of care multiple myeloma 
chemotherapy, to determine whether efficacy can be further increased with a 




Chapter 4: Determine the extent of NE and P3 uptake and 
PR1 cross-presentation by multiple myeloma 
 
The following chapter is based on my publication, used with permission granted 
by AACR Journals.  
 
Alatrash, G.1, Perakis, A.A.1, Kerros, C., Peters, H.L., Sukhumalchandra, P., 
Zhang, M., Jakher, H., Zope, M., Patenia, R., Sergeeva, A., Yi, S., Young, K.H., 
Philips, A.V., Cernosek, A.M., Garber, H.R., Qiao, N., Weng, J., St John, L.S., 
Lu, S., Clise-Dwyer, K., Mittendorf, E.A., Ma, Q. & Molldrem, J.J. Targeting the 
Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple 
Myeloma. Clin Cancer Res 24, 3386-3396 (2018). 
 
 
4.1 Multiple myeloma cells lacking endogenous NE and P3 internalize 
exogenous proteins 
 
To determine if multiple myeloma cells express NE and P3, a panel of 
multiple myeloma cell lines was analyzed for endogenous expression of these 
PGP. Our data indicate that NE and P3 are absent in multiple myeloma cells at 
the transcript and protein levels (Figure 2A and B). These findings are in 
agreement with reports from the Cancer Cell Line Encyclopedia,59 which confirm 
the lack of NE and P3 in multiple myeloma (Figure 3A and B). The absence of 
NE and P3 in multiple myeloma is expected since multiple myeloma is of 
lymphoid origin, which is known to be deficient in myeloid primary granule 
proteins.60 The myelomonocytic U937 leukemia cell line that endogenously 
expresses NE and P3 was used as a positive control in these experiments.  
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Figure 2. Multiple myeloma cells lack endogenous NE and P3. Protein (A) 
and mRNA (B) was extracted from multiple myeloma cell lines. (A) Immunoblots 
demonstrate lack of NE and P3 proteins in whole cell lysates from seven different 
multiple myeloma cell lines. Gels were loaded with 20 μg of protein. (B) RT-PCR 
was performed using NE and P3 primers, which shows lack of NE and P3 mRNA 
expression in multiple myeloma cell lines. U937 myelomonocytic AML cell line 
was used as a positive control. β-actin was used as a loading control. The first 





























































Figure 3. Transcript expression of NE and P3 genes in Cancer Cell Line 
Encyclopedia (CCLE). Transcript expression of ELANE (A) and PRNT3 (B) 
from cell lines was accessed from the CCLE for the following hematological 
malignancies: multiple myeloma, (MM, 25), acute myeloid leukemia (AML, 36), 
acute lymphoblastic leukemia (ALL, 16), Burkett’s lymphoma (11), chronic 
myelogenous leukemia (CML, 14), B cell lymphoma (42), T cell lymphoma (5), T 
cell leukemia (16), chronic lymphocytic leukemia (CLL, 3). Parentheses indicate 













































































































4.2 HLA-A2+ multiple myeloma cells take up and cross-present NE and P3 
from soluble and cell-associated sources 
 
Since we previously showed that solid tumors and B cells take up NE and 
P3,40,41,43,53,61,62 we next tested whether multiple myeloma cells take up NE and 
P3, the first step in antigen cross-presentation. We co-cultured a number of 
multiple myeloma cell lines with soluble NE or P3 over increasing durations. Flow 
cytometry analysis of intracellular NE and P3 staining demonstrates that NE and 
P3 are taken up by multiple myeloma (Figure 4A and B). Time-dependent 
internalization of NE and P3 is observed, with a marked difference in the 
magnitude of uptake between NE and P3. Our data indicates that soluble P3 is 
more efficiently internalized compared to NE by multiple myeloma cell lines. The 
uptake of both proteins is sustained throughout the duration of the cultures. The 
kinetics and degree of NE and P3 uptake by the multiple myeloma cell lines 
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Figure 4. Multiple myeloma cells internalize exogenous NE and P3.  
Flow cytometry detected intracellular NE and P3 in multiple myeloma cell lines 
following culture with NE (10 μg/mL) (A) or P3 (10 μg/mL) (B). After incubation, 
cells were permeabilized and stained with either anti-NE or anti-P3 antibodies. 
Graphs display the mean ± SEM fold increase in median fluorescence intensity 
(MFI) over untreated cells from triplicate wells from six independent experiments.  
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Since PR1 is an HLA-A2-restricted epitope, we focused our cross-
presentation studies on the HLA-A2+ (i.e., HLA-A*0201) U266 multiple myeloma 
cell line. In agreement with the panel of multiple myeloma cell lines we examined 
(Figure 4A and B) we confirmed the internalization of soluble and PMN-
associated NE and P3 by U266 cells (Figure 5A and B; Figure 6A and B). 
Previously, we demonstrated that solid tumor cells can cross-present PR1 from 
both soluble and cell-associated sources of NE and P3.40,43 These findings were 
recapitulated in the U266 multiple myeloma cells that were co-cultured with 
soluble NE, P3 or irradiated HLA-A2- PMN, the latter serving as the cellular 
source of NE and P3 that lack endogenous PR1 (Figure 7A and B).  
 
As shown previously, cross-presentation was demonstrated by staining 
cells with anti-PR1/HLA-A2 Alexa-647-conjugated antibody.40 Due to the unique 
and inherent HLA-binding properties of TCR-like antibodies, we have observed 
low-affinity binding of 8F4 to HLA-A2 in other cell lines,40,50 and also observed 
low background 8F4 staining in non-pulsed U266 cells. However, to highlight the 
specificity of 8F4 for PR1/HLA-A2 complex, the HLA-A2- multiple myeloma cell 
lines, OPM-2 and RPMI 8226 were also co-cultured with HLA-A2- PMN and 
examined for cross-presentation (Figure 8). Thus, these data confirm NE and P3 
internalization by U266 multiple myeloma cells.  Notably, there were differences 
in the magnitude of internalization between NE or P3 based on the protein 
source: PMN-derived NE achieved higher intracellular levels than soluble NE and 
was comparable to the uptake of PMN-derived P3.  
 35 































 Combined U266 NE P3 line
P3 Pulsed
NE Pulsed
A Soluble NE and P3 












Combined NE and P3
NE stained
P3 stained
B Cell-Associated NE and P3 
Time (hours) 
Time (hours) 
 *  * 
  *  * *  * 
 36 
Figure 5. HLA-A2+ U266 cell line takes up NE and P3 from soluble and cell-
associated sources. HLA-A2+ U266 multiple myeloma cell line was cultured 
with soluble NE (10 μg/mL) or P3 (10 μg/mL) (A), or irradiated HLA-A2- PMN (B) 
at the indicated time points. Cells were permeabilized, stained with anti-NE or 
anti-P3 antibody and analyzed by flow cytometry. For cell-associated uptake, 
light scatter and HLA-A2 staining seen on flow cytometry provided a clear 
distinction between PMN and U266 cells. PMN alone were used as a positive 
control for NE and P3 (white bars). ANOVA was performed using Prism 6.0 
software (*P<0.05). Data are means ± SEM from triplicate experiments.   
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Figure 6. NE and P3 localize within the cell following co-culture with U266 
multiple cells. HLA-A2+ U266 multiple myeloma cell line was cultured with 
soluble NE (10 μg/mL) (A) or P3 (10 μg/mL) (B). Cells were either surface 
stained or were permeabilized and then stained with anti-NE or anti-P3 antibody 
and analyzed by flow cytometry to confirm uptake. 
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Figure 7. HLA-A2+ U266 cell cross-presents NE and P3 from soluble and 
cell-associated sources. U266 cells were cultured with soluble NE or P3 (10 
μg/mL) (A) or irradiated PMN (B) then analyzed for expression of surface 
PR1/HLA-A2 using 8F4-Alexa 647. Mean ± SEM fold increase of the median 
fluorescence intensity (MFI) of PR1/HLA-A2 is shown from duplicate 
experiments. Time “0” indicates untreated cells. ANOVA test was performed 
using Prism 6.0 software (*P<0.05).  
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Figure 8. Absence of PR1 cross-presentation in HLA-A2 negative multiple 





Figure 8. Absence of PR1 cross-presentation in HLA-A2 negative multiple 
myeloma cell lines. HLA-A2 negative OPM-2 and RPMI 8226 multiple myeloma 
cell lines were cultured with irradiated HLA-A2 negative PMN at the indicated 
time points then analyzed for expression of surface PR1/HLA-A2 using 8F4-Alex 
647. Mean ± SEM of the median fluorescence intensity (MFI) of PR1/HLA-A2 is 
shown from a representative experiment that was performed in duplicate. Time 
“0” indicates untreated cells. U937-A2+ cell line was used as a positive control for 
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4.3 Cross-presentation by multiple myeloma involves the proteasome and 
Golgi/ER. 
 
Cross-presentation involves distinct, well-defined pathways that utilize the 
proteasome and ER/Golgi.63-65 The proteasome plays an important role in 
antigen cross-presentation by cleaving intracellular proteins into small, 8-11 
amino acid peptides, which are transported into the ER by the TAP1/2 complex. 
In the ER, peptides are loaded onto HLA class I molecules using components of 
the antigen processing machinery and are then exported to the cell surface via 
the Golgi. We hypothesized that NE and P3 cross-presentation involves 
proteasome and ER/Golgi shuttling, as previously shown for NE and P3 cross-
presentation by solid tumors and APCs.40,41 Our data confirm that multiple 
myeloma utilizes the ER/Golgi and proteasome for NE and P3 cross-
presentation, since incubation of cells with lactacystin, a proteasome inhibitor, 
and brefeldin A, which inhibits ER to Golgi antegrade transport, both decreased 
PR1/HLA-A2 expression (Figure 9A and B).  
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Figure 9. Proteasome and ER/Golgi are involved in the cross-presentation 
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Figure 9. Proteasome and ER/Golgi are involved in the cross-presentation 
of NE and P3 by U266 multiple myeloma cells. U266 multiple myeloma cells 
were cultured for 24 hours in media containing NE or P3 (10 μg/mL) and the 
antigen processing machinery inhibitors lactacystin (proteasome inhibitor) or 
brefeldin A (ER/Golgi transport inhibitor) (A, B). PBMC were cultured with U266 
to serve as a negative control, since PBMC lack NE and P3. Cells were then 
analyzed using flow cytometry for expression of PR1/HLA-A2 after surface 
staining with 8F4-Alexa-647. Mean ± SEM of the median fluorescence intensity 
(MFI) of PR1/HLA-A2 is shown from duplicate wells from 3 separate 




Next, we translated our in vitro studies into a clinically relevant system by 
examining PMN as the source for NE and P3 and using bortezomib, a 
proteasome inhibitor approved for treatment of multiple myeloma. In agreement 
with our findings with lactacystin, bortezomib reduced PR1/HLA-A2 on the U266 
myeloma cell surface (Figure 10). Additionally, the IMiD lenalidomide did not alter 
surface levels of PR1/HLA-A2 on U266 after co-culture with PMN (Figure 11). 
We also observed a consistent decrease in the surface expression of overall 
HLA-A2 due to inhibition of the proteasome after treatment with both lactacystin 
and bortezomib (Figure 12A and B). However, surface HLA-A2 expression was 
unaffected by brefeldin A or lenalidomide (Figure 13A and B). Since conventional 
antigen cross-presentation mechanisms employ proteasome,37 it is not surprising 
that overall expression of HLA-A2 decreases with the use of lactacystin and 
bortezomib, and highlights the role of the proteasome in PR1 cross-presentation.  
  
 46 
Figure 10. Bortezomib reduces PR1/HLA-A2 expression on the cell surface 
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Figure 10. Bortezomib reduces PR1/HLA-A2 expression on the cell surface 
of U266 multiple myeloma cells. U266 multiple myeloma cells were cultured for 
24 hours with PMN at a 1:1 U266:PMN ratio in media containing bortezomib 
(Bor).  PBMC were cultured with U266 to serve as a negative control, since 
PBMC lack NE and P3. Cells were then analyzed using flow cytometry for 
expression of PR1/HLA-A2 after surface staining with 8F4-Alexa-647. Mean ± 
SEM of the median fluorescence intensity (MFI) of PR1/HLA-A2 is shown from 
duplicate wells from 3 separate experiments. ANOVA test was performed using 
Prism 6.0 software (*P<0.05). 
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Figure 11. Lenalidomide does not reduce PR1/HLA-A2 expression on the 
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Figure 11. Lenalidomide does not reduce PR1/HLA-A2 expression on the 
cell surface of U266 multiple myeloma cells. U266 multiple myeloma cells 
were cultured for 24 hours with PMN at a 1:1 U266:PMN ratio in media 
containing lenalidomide (Len).  PBMC were cultured with U266 to serve as a 
negative control, since PBMC lack NE and P3. Cells were then analyzed using 
flow cytometry for expression of PR1/HLA-A2 after surface staining with 8F4-
Alexa-647. Mean ± SEM of the median fluorescence intensity (MFI) of PR1/HLA-
A2 is shown from duplicate wells from 3 separate experiments. ANOVA test was 
performed using Prism 6.0 software. NS, not significant. 
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Figure 12. HLA-A2 expression on U266 is reduced after addition of 
proteasome inhibitors. U266 multiple myeloma cells were cultured for 24 hours 
in media containing NE or P3 (10 μg/mL) and lactacystin (proteasome inhibitor) 
(A) or were cultured for 24 hours with PMN at a 1:1 U266:PMN ratio in media 
containing bortezomib (Bor) (B). Cells were then analyzed using flow cytometry 
for expression of HLA-A2. Mean ± SEM of the median fluorescence intensity 
(MFI) of HLA-A2 is shown from duplicate wells from 3 separate experiments. 
ANOVA test was performed using Prism 6.0 software (**P<0.01, ***P<0.001). 
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Figure 13. HLA-A2 expression on U266 is not reduced after addition of 
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Figure 13. HLA-A2 expression on U266 is not reduced after addition of 
brefeldin A or lenalidomide. U266 multiple myeloma cells were cultured for 24 
hours in media containing NE or P3 (10 μg/mL) and brefeldin A (ER/Golgi 
transport inhibitor) (A) or were cultured for 24 hours with PMN at a 1:1 
U266:PMN ratio in media containing lenalidomide (Len) (B). Cells were then 
analyzed using flow cytometry for expression of HLA-A2. Mean ± SEM of the 
median fluorescence intensity (MFI) of HLA-A2 is shown from duplicate wells 
from 3 separate experiments. ANOVA test was performed using Prism 6.0 




4.4 PR1 cross-presentation by multiple myeloma is TAP-dependent 
Since we previously demonstrated that PR1 cross-presentation utilizes the 
proteasome and ER/Golgi, conventional components of antigen presentation, we 
further investigated the role of the other antigen presentation machinery proteins 
(APM). As discussed earlier in this work, cross-presentation can utilize TAP to 
transport peptides from the cytosol into the ER for HLA loading. However, there 
also are other described peptide loading mechanisms that are TAP-independent. 
To characterize the role of TAP in multiple myeloma cross-presentation, we 
knocked-down TAP expression in U266 cells by siRNA. si-TAP U266 cells were 
then cultured in media supplemented with soluble NE to facilitate cross-
presentation. Calcein-AM cytotoxicity assays show significant reduction in PR1-
CTL recognition at 5:1 E:T ratios. This indicates that si-TAP U266 cells pulsed 
with NE were less susceptible to killing by PR1-CTL than si-control U266 cells 
(Figure 14A). These data suggest that TAP is required for cross-presentation of 
NE and PR1/HLA-A2 expression by U266. Sufficient TAP knock-down in U266 
was confirmed by western blot (Figure 14B). Additionally, the total HLA 
expression was unaffected by siRNA further suggesting these observations are 
not due to global change in peptide HLA expression (Figure 14B). 
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Figure 14. TAP knock-down in U266 results in decreased PR1/HLA-A2 
expression and PR1-mediated killing. 
  


































Figure 14. TAP knock-down in U266 results in decreased PR1/HLA-A2 
expression and PR1-mediated killing. (A) TAP1 was knocked-down in U266 
cells using siRNA for TAP1. After 48 hours, U266 cells we cultured with or 
without soluble NE (10µg/mL) supplemented media for 24 hours. Calcein AM 
cytotoxicity assays using PR1-specific CTL were then performed at varying 
effetor:target (E:T) ratios. Significantly higher killing of target cells was seen at 
the 5:1 E:T ratios for the si-control U266 +NE group compared to both si-TAP1 
U266+NE and si-control U266 untreated group. (*P<0.05). Statistical analysis 
was performed using ANOVA test. (B) Western blot analysis confirms sufficient 
knock-down of TAP1 was achieved in U266 cells when treated with si-TAP1. 
GAPDH was used as a loading control. 
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Additionally, we sought to investigate whether the other APM proteins 
were differentially expressed in multiple myeloma patients. To this end, we 
analyzed the expression of the core components of the APM: calnexin, TAP, 
tapasin, LMP2/7 in patient multiple myeloma cells using western blot (Figure 15). 
Expression among the APM proteins, LMP7, LMP2, and tapasin were shown to 
be upregulated in multiple myeloma patients when compared to healthy donor B 
cells.  We did not observe protein expression differences in the other APM 
components, calnexin and HLA. However, we did observe a lower expressed 
isoform of calnexin in Patient 3 who also showed decreased HLA expression. We 
further investigated the expression of calnexin and HLA among 10 other multiple 
myeloma patients by western blot (Figure 16). Our data show that two prominent 
isoforms of calnexin are expressed in multiple myeloma patient cells and this is 
correlated with lower HLA expression in patients that express the lower 
molecular weight isoform of calnexin. Interestingly, the lower HLA expression 
pattern observed in these multiple myeloma patients resembled a similar double-
band phenotype of immature HLA molecules when retained in the ER.66 This 
expression pattern may suggest a potential dominant negative effect mediated 
through improper chaperone functions by an alternative calnexin isoform where 
immature HLA molecules are retained in the ER and prevented from proper 
folding and egress to the cell surface.  
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Figure 15. APM proteins LMP7, LMP2, and tapasin are upregulated in 
















Figure 15. APM proteins LMP7, LMP2, and tapasin are upregulated in 
multiple myeloma patients. The expression of the major proteins that comprise 
the antigen presentation machinery (APM) were analyzed via western blotting.  
Whole cell lysates were generated from CD138+ enriched cells from the bone 
marrow of newly diagnosed multiple myeloma patients. B cells sorted from 
healthy donor peripheral blood monocytes were used as a control for non-
malignant protein expression levels. Patient whole cell lysates were loaded and 
separated by gel electrophoresis under reducing conditions. β-actin was used as 
a loading control. Expression among the APM proteins and across patients 
appears variable, with expression observed to be upregulated in some proteins 
(LMP7, LMP2, Tapasin) or unchanged (HLA, Calnexin). 
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Figure 16. Multiple myeloma patients express different isoforms of 
calnexin. Whole cell protein lysates were generated from CD138+ cells of 10 
newly diagnosed multiple myeloma patients as previously described in Figure 15. 
Western blotting was performed using antibodies against calnexin, HLA-ABC and 
β-actin as a loading control. Western blot analysis indicates two isoforms of 
calnexin expressed in multiple myeloma patients, with the lower molecular weight 








































4.5 Chapter 4 Summary 
 
 Collectively our data demonstrates that multiple myeloma is capable of 
cross-presenting exogenous antigens. We have modeled this phenomenon by 
tracking the expression of two myeloid-restricted serine proteases, NE and P3. 
Multiple myeloma cells do not endogenously express NE or P3, but are capable 
of taking up these proteins from the extracellular environment and internalizing 
them in the cytoplasm. Furthermore, NE and P3 can be processed in a 
proteasome-dependent manner, leading to the expression of the PR1 antigen in 
the context of HLA-A2 on the multiple myeloma cell surface.  
 
 Importantly, multiple myeloma relies on the proteasome for effective 
cross-presentation of NE and P3, as use of proteasome inhibitors, lactacystin 
and bortezomib, muted the expression of PR1/HLA-A2 in U266 multiple myeloma 
cells. Additionally, use of Golgi transport inhibitor, brefeldin A, revealed that 
multiple myeloma cross-presentation also relies on the canonical ER to Golgi 
shuttling pathway for PR1/HLA-A2 surface expression. Our data also supports a 
TAP-dependent mechanism for PR1 cross-presentation as silencing TAP in 
U266 resulted in decreased PR1/HLA-A2 and PR1-CTL recognition. Treatment 
with the IMiD lenalidomide did not affect the ability of U266 cells to cross-present 
NE and P3 as there was no observed decrease in PR1/HLA-A2 expression.  
  
 Overall our data thus far have revealed a unique mechanism by which 
multiple myeloma cells can express a novel antigen, PR1, via cross-presentation. 
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Chapter 5: Evaluate the susceptibility of multiple myeloma to 
PR1-targeting immunotherapies 
 
The following chapter is based on my publication, used with permission granted 
by AACR Journals.  
 
Alatrash, G.1, Perakis, A.A.1, Kerros, C., Peters, H.L., Sukhumalchandra, P., 
Zhang, M., Jakher, H., Zope, M., Patenia, R., Sergeeva, A., Yi, S., Young, K.H., 
Philips, A.V., Cernosek, A.M., Garber, H.R., Qiao, N., Weng, J., St John, L.S., 
Lu, S., Clise-Dwyer, K., Mittendorf, E.A., Ma, Q. & Molldrem, J.J. Targeting the 
Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple 
Myeloma. Clin Cancer Res 24, 3386-3396 (2018). 
 
 
5.1 PR1 cross-presentation increases the susceptibility of multiple 
myeloma to PR1-CTL and 8F4 antibody 
 
Immunotherapy targeting PR1 has shown promising efficacy in the 
treatment of myeloid malignancies.49,50,67,68 Thus, we investigated whether PR1 
cross-presentation by multiple myeloma cells could lead to their lysis by PR1-
CTL and the complement-fixing, anti-PR1/HLA-A2 8F4 antibody. Calcein-AM 
cytotoxicity assays demonstrate that cross-presentation of NE and P3 by U266 
cells renders them susceptible to killing by PR1-CTL and 8F4 antibody in a dose-
dependent manner (Figure 17). Specifically, NE enhanced the killing of U266 
cells by PR1-CTL at 10:1 and 5:1 effector: target (E:T) ratios, when compared to 
untreated or ova-supplemented U266 cells (Figure 17A). The efficacy of PR1-
CTL in eliminating PR1-cross-presenting multiple myeloma cells was further 
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validated by U266 cells that were supplemented with P3, where killing was 
demonstrated at the 10:1, 5:1 and 2.5:1 E:T ratios (Figure 17A).  
 
Since we have previously shown that the anti-PR1/HLA-A2 antibody (8F4) 
lyses malignant cells via CDC,40,50 we tested whether multiple myeloma could be 
killed by 8F4. In a standard CDC assay, we demonstrate significantly higher 8F4-
mediated killing of U266 target cells that were cultured with NE and P3 (Figure 
17B). Combined, these studies show that multiple myeloma is rendered 
susceptible to killing by PR1-targeting immunotherapies and further confirm PR1 
cross-presentation by multiple myeloma.  
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Figure 17. PR1 cross-presentation increases the susceptibility of multiple 
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Figure 17. PR1 cross-presentation increases the susceptibility of multiple 
myeloma to PR1-CTL and anti-PR1/HLA-A2 antibody. (A) When comparing 
PR1-CTL killing of target U266 cells supplemented with NE or P3 to ova-
supplemented U266 and U266 cells alone, significantly higher killing of target 
cells was seen at the 10:1 and 5:1 E:T ratios for the U266 + NE group and 10:1, 
5:1 and 2.5:1 E:T ratios for the U266 + P3 group (*P<0.05). (B) Similarly, when 
comparing 8F4 killing of NE-supplemented and P3-supplemented U266 target 
cells to ova-supplemented U266 and U266 cells alone, significantly higher killing 
of target cells was seen at the 10 μg/mL and 5 μg/mL 8F4 concentrations for the 
NE-supplemented group and at the 10 μg/mL, 5 μg/mL and 2.5 μg/mL 8F4 
concentrations for the P3-supplemented group (*P<0.05). Significantly higher 
killing was also demonstrated when comparing P3-supplemented U266 to ova-
supplemented U266 at the 1.25 μg/mL 8F4 concentration.  Statistical analysis 
was performed using ANOVA test. 
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5.2 PR1-CTL and 8F4 antibody reduce multiple myeloma burden in 
xenograft mice 
 
Since PR1 cross-presentation by U266 increases susceptibility to PR1 
targeting immunotherapy in vitro, we next investigated whether PR1 can be 
targeted in vivo using a multiple myeloma U266 xenograft mouse model.54 To 
test this hypothesis, we utilized NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice, 
which contain bone marrow resident PMN, providing an available source of NE 
and P3 for cross-presentation. Additionally, the murine PR1 sequence is 
homologous to the human sequence (VLQELNVTV), and murine CTL can 
recognize PR1/HLA-A2 and are able to be expanded after vaccination.69 In this 
xenograft model, GFP and luciferase transduced U266 cells home to various 
bone marrow tissues such as the tibia, fibula, spine, and skull of NSG mice within 
two weeks of engraftment. Multiple myeloma progression can be monitored by 
IgE ELISA, as U266 is an IgE secreting multiple myeloma subtype, and by 
bioluminescent imaging (BLI, Figure 18). 
 
After confirming U266 engraftment in the bone marrow and following 
treatment with 8F4, we demonstrate a significantly decreased U266 multiple 
myeloma burden, as shown by a decrease in the concentration of human IgE in 
mouse serum in comparison with isotype and untreated groups (Figure 19A). 
Furthermore, 8F4 treatment also noticeably reduced the percent of multiple 
myeloma cells in mouse bone marrow in comparison to mice treated with isotype 
and untreated mice (Figure 19B). Similar results were also seen using PR1-CTL 
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(Figure 19C). U266 multiple myeloma cells were identified as human CD45+ and 
mouse CD45- cells (Figure 20A and B). Additionally, BLI measurements 
corroborated these findings (Figure 21). We also observed significant prolonged 
survival in mice treated with 8F4 compared to mice that received isotype 
antibody (Figure 22). Together, these data suggest that 8F4 and PR1-CTL are a 
feasible and effective therapy for HLA-A2+ multiple myeloma.   
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Figure 18. U266 multiple myeloma xenograft model and 8F4 treatment 
schema. (A) Starting on day 0, female NSG mice were sub-lethally irradiated 
(250 cGy) prior to U266 engraftment. After 24 hours, on day 1, NSG mice were 
engrafted with 2 x 106 U266 cells via tail vein injection. Engraftment was 
monitored and confirmed on days 14-21 by both IgE ELISA and bioluminescent 
imaging (BLI, IVIS100). Mice were then received 10 total injections over 21 days 
of 8F4 antibody or IgG isotype control (Herceptin). Disease progression and 
treatment effects were monitored by ELISA and BLI. Mice were sacrificed and 
bone marrow harvested by day 56. (B) Human IgE concentrations in mouse 
serum were analyzed by ELISA. Mice that were engrafted with U266 cells show 
increasing accumulation of human IgE over time compared to mice who were 
unengrafted. (C) U266 cells recovered from mouse bone marrow can be 
identified from mouse bone marrow by mouse CD45 (mCD45)-negative, human 







































































































































Figure 19. 8F4 antibody and PR1-CTL reduce multiple myeloma in U266 
xenograft mice. U266 multiple myeloma xenograft mice were established and 
treated with (A, B) 8F4 antibody, IgG isotype control, or (C) PR1-CTL. (A) Mouse 
serum was collected by tail bleeding and separated by centrifugation. Human IgE 
was measured using ELISA. 8F4 treated mice show reduced circulating human 
IgE levels compared to isotype and untreated mice (****P<0.0001). (B) At the 
end of treatment mice were sacrificed and bone marrow was harvested, a single 
cell suspension of bone marrow was generated and analyzed by flow cytometry 
for residual U266 cells. 8F4 treated mice show reduced percentage of U266 cells 
in the bone marrow compared to isotype and untreated mice (****P<0.0001). 
Percent of myeloma cells were normalized to untreated mouse bone marrow for 
each experiment. (C) Mouse bone marrow was analyzed by flow cytometry after 
treatment with PR1-CTL. PR1-CTL-treated mice show reduced percentage of 
U266 cells in the bone marrow compared to mice treated with irrelevant peptide-
CTL (**P<0.01) or untreated mice (***P<0.001). Statistical analysis was 




















Figure 20. Gating strategy for identifying U266 cells in mouse bone marrow. 
Gating strategy utilized to identify U266 cells in mouse bone marrow. U266 cells 
were defined as human CD45+ mouse CD45-.  Bone marrow of a representative 
mouse that was untreated (A, PBS) shows a robust multiple myeloma burden 
compared to the bone marrow of an 8F4 treated mouse (B). 
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Figure 21. 8F4 antibody impedes multiple myeloma growth in U266 
xenograft mice. 8F4 antibody treatment reduced multiple myeloma burden and 
growth. BLI images were captured using an IVIS 100 at the Small Animal 
Imaging Facility at MD Anderson Cancer center. Bioluminescent images were 
analyzed using Living Image software (PerkinElmer). All images were set to the 
same scale before analysis. (A) Representative images of mice treated with 
either 8F4 antibody or isotype control. (B) BLI images were quantified by 
measuring total flux (p/s) from ventral images of mice treated with 8F4 antibody 
or isotype control. 8F4 treated mice showed reduced multiple myeloma growth 
compared to isotype treated mice (****P<0.0001). Statistical analysis was 
performed using two-tailed T test. 
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Figure 22. 8F4 antibody extends survival in U266 xenograft mice. U266 
xenograft mice were established and treated as previously described in Figure 18 
and Figure 19. Time of death for each animal was determined when the mouse 
became moribund. Kaplan-Meier curves show longer median survival for mice 
treated with 8F4 antibody (median 99 days, n=10) compared to mice that 
received IgG isotype control antibody (Herceptin; median 77 days, n=20) 
(****P<0.0001).  
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5.3 8F4 antibody and bortezomib combination therapy results in an 
increased anti-myeloma effect 
 
As combination therapy for multiple myeloma is commonplace already, 
and new multiple myeloma therapies are frequently being used in combination, 
we aimed to further our understanding of how 8F4 could be integrated into 
standard of care treatments. To this end, we sought to investigate the interaction 
between 8F4 and bortezomib and identify any potential cooperative effects for 
treating multiple myeloma. First we observed an additive anti-myeloma effect 
when 8F4 is combined with bortezomib using an Annexin V flow-based apoptosis 
assay in vitro (Figure 23). Greater cell death was noted in U266 cells that were 
co-cultured with PMN and received combination therapy compared to cells that 
received either 8F4 or bortezomib single agent therapy alone.  
 
Furthermore, we translated our findings using our U266 xenograft model 
and found that combination therapy of 8F4 and bortezomib more effectively 
reduces the myeloma burden in xenograft mice as well as prolongs survival 
(Figure 24).  As multiple myeloma therapies continue to improve, we also 
investigated whether improved beneficiary effects could be achieved with next-
generation proteasome inhibitors, such as carfilzomib. While not significant at 
this time, mice that received 8F4 in combination with carfilzomib appear to have 
a longer survival rate than those that received bortezomib (Figure 24B). 
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Figure 23. 8F4 and bortezomib combination has an additive anti-myeloma 
activity. U266 cells were co-cultured with irradiated PMN 24 hours prior to drug 
exposure to facilitate PR1 cross-presentation (U266 +PMN) or unpulsed as 
control. U937-WT and U937-A2 AML cell lines were used as negative and 
positive controls for 8F4 mediated lysis respectively.  U266 + PMN cells that 
received 8F4 and bortezomib combination therapy showed increased apoptosis 
via Annexin V and propidium iodide staining compared to U266 + PMN cells that 
received 8F4 alone (***P<0.001) or bortezomib alone (***P<0.001). Mean ± SEM 
of the sum percent of Annexin V+ and Annexin V+ propidium iodide+ is shown 
from triplicate wells. Figure is representative of three independent experiments. 
Statistical analysis was performed using ANOVA test. NS, not significant.  
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Figure 24. 8F4 and bortezomib combination therapy more effectively 
















































































  ** 
  ** 




Figure 24. 8F4 and bortezomib combination therapy more effectively 
reduces the multiple myeloma burden in xenograft mice and prolongs 
survival. U266 xenograft mice were established as previously described in 
Figure 18 and Figure 19. (A) Mice were treated with low dose 8F4 antibody (0.05 
mg/kg) alone or in combination with bortezomib (Bor, 0.025 mg/kg) or isotype 
control antibody (1 mg/kg) alone or in combination with bortezomib (0.025 
mg/kg). Combination therapy of 8F4 and bortezomib showed improved reduction 
in human IgE serum levels in mice compared to those that received single agent 
treatment of 8F4 (*P<0.05) and single agent treatment of bortezomib (**P<0.01). 
Statistical analysis was performed using ANOVA test. (B) Prolonged survival was 
measured up to 120 days in xenograft mice that received combination therapy. 
Mice were treated with 8F4 antibody (10 mg/kg) alone or in combination with 
bortezomib (0.025 mg/kg). Mice were also treated with 8F4 in combination with 
next generation proteasome inhibitor, carfilzomib (Car, 0.025 mg/kg) 
respectively. Time of death for each animal was determined when the mouse 
became moribund. Kaplan-Meier curves show longer median survival for mice 
treated with 8F4 antibody in combination with bortezomib (median 111.5 days, 
n=5, *P<0.05) or carfilzomib (median undefined, n=5, **P<0.01) compared to 
mice that received 8F4 antibody alone (median 96 days, n=5).  
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5.4 PR1/HLA-A2 and PR1-CTL are detected in multiple myeloma patients 
 
We next investigated whether PR1 could be detected in the bone marrow 
(BM) from patients with multiple myeloma, and if immunity to PR1 (i.e., PR1-CTL) 
could be detected in peripheral blood (PB) from patients with multiple myeloma 
following allo-SCT. We were able to detect PR1/HLA-A2 on the surface of 4 of 8 
HLA-A2+ patients with multiple myeloma (Table 1; Figure 25). To highlight the 
low background staining and high specificity for the PR1/HLA-A2 combined 
epitope of the 8F4 antibody, control staining and confocal imaging is was 
performed on U266 cells pulsed or non pulsed with PMN (Figure 26).  
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Stage II Normal diploid Yes 6 - 
UPN2 IgG 
lambda 
Stage II Del 13 Yes 6 - 
UPN3 IgG 
kappa 
Stage I Normal diploid Yes 4 - 
UPN4 IgG 
lambda 
Stage III Del 17p13 Yes 1 - 
UPN5 IgA 
kappa 
Stage II Del 13 Yes 0 + 
UPN6 IgG 
kappa 
Stage III Normal diploid Yes 0 + 
UPN7 IgG 
lambda 
Stage III Del 13; t(4;14) Yes 1 + 
UPN8 IgA 
kappa 
Stage II Del 13; Del 
17p13 
Yes 5 + 
 
*Number of treatments prior to sample acquisition. 
Abbreviations: UPN, unique patient number; MM, multiple myeloma; Del, 
deletion; N/A, not available; t, translocation. 
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Figure 25. PR1/HLA-A2 is presented on the surface of patient multiple 
myeloma cells. Bone marrow smears from 2 patients with multiple myeloma 
were stained with (A) anti-PR1/HLA-A2 (8F4)-647 (red) and anti-HLA-A2-Alex-
488 (green) or (B) anti-PR1/HLA-A2 (8F4)-647 (red) and anti-CD138-Alex-488 
(green) and then imaged using confocal laser microscopy. PR1/HLA-A2 is 
expressed by multiple myeloma cells as shown by the co-staining of 8F4 with 





























Figure 26. U266 cross-presents PR1 after exposure to NE/P3 from PMN co-
culture. Control staining of U266 cell line (A) co-cultured with PMN or (B) 
untreated was evaluated by confocal microscopy. Immunofluorescence staining 
for Alexa 647-8F4 (red), FITC-HLA-A2 (green) and DAPI stained nuclei (blue) is 





To determine whether PR1-CTL could be detected in PB from HLA-A2+ 
patients with multiple myeloma, we used PR1/HLA-A2 dextramer staining and 
showed PR1-CTL in the PB from 10 of 14 multiple myeloma patients who 
received allo-SCT (Table 2; Figure 27 and Figure 28).  The median frequency of 
PR1-CTL in these multiple myeloma patients was 0.053% of CD8+ T cells 
(Range, 0%-1.67%), which is higher than the frequency of PR1-CTL reported in 




Table 2. PR1-CTL frequency in HLA-A2+ multiple myeloma patients 
following allogeneic stem cell transplantation. 
 
Patient MM subtype Days post 
allo-SCT 
Alive status % dextramer staining 
UPN4 IgG lambda 716 No 0.00282 
UPN8 IgA kappa 378 No 0.125 
UPN9 IgG lambda 490 No 0.0192 
UPN10 Unspecified 1089 No 0.002 
UPN11 Lambda light chain 97 Yes 0.255 
UPN12 IgG kappa 266 Yes 0.231 
UPN13 IgG kappa 197 Yes 1.668 
UPN14 IgA lambda 247 Yes 0.088 
UPN15 Kappa light chain 176 No 0.0867 
UPN16 Kappa light chain 77 No 0 
UPN17 IgG kappa 379 No 0 
UPN18 IgG kappa 93 No 0 
UPN19 IgA lambda 718 Yes 0.681 
UPN20 IgA kappa 163 No 0 
 
Abbreviations: UPN, unique patient number; MM, multiple myeloma; allo-SCT, 
allogeneic stem cell transplantation 
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Figure 27. Gating strategy used to determine PR1-CTL frequency in 
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Figure 27. Gating strategy used to determine PR1-CTL frequency in 
peripheral blood of multiple myeloma patients following allogeneic stem 
cell transplantation. Cells were stained with CD3, CD8 and PR1/HLA-A2-
dextramer and the lineage (Lin) markers CD4, CD14, CD16 and CD19. The 
frequency of PR1/HLA-A2 dextramer+ cells (i.e. PR1-CTL) was determined as 
the percent of cells from live, Lin-, CD3+, CD8+ cells.  
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Figure 28. PR1 dextramer plots of multiple myeloma patients following 














Figure 28. PR1 dextramer plots of multiple myeloma patients following 
allogeneic stem cell transplantation. Four dextramer plots are representative 
of the 14 multiple myeloma patients analyzed are shown. Bottom plots 
represents the FMO staining control for the respective patient plot above. Cells 
were stained with CD3, CD8 and PR1/HLA-A2-dextramer and the lineage (Lin) 
markers CD4, CD14, CD16 and CD19. The frequency of PR1/HLA-A2 
dextramer+ cells (i.e. PR1-CTL) was determined as the percent of cells from live, 

























































































































































Furthermore, using CD45RA and CCR7 staining, PR1-CTL phenotype 
was analyzed in 4 of the patients and demonstrated primarily an effector memory 
phenotype of the PR1-CTL (Figure 29). Additionally, we investigated whether 
PR1-CTL are present in the PB of HLA-A2+ multiple myeloma patients after 
receiving autologous stem cell transplant (auto-SCT) (Table 3; Figure 30). PR1-
CTL frequencies were detected by PR1/HLA-A2 tetramer staining in all 18 
multiple myeloma patients following auto-SCT. The median frequency of PR1-
CTL in these patients was 0.205% (Range, 0.076%-1.31%). These patient data 
suggest that bone marrow-derived NE and P3 is taken up and cross-presented 
by multiple myeloma, and that immunity to PR1 is elicited in multiple myeloma 
patients following SCT.  
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Figure 29. Phenotype of PR1-CTL in patients following allo-SCT. Four 
multiple myeloma patient samples were stained for PR1-CTL using PR1/HLA-A2 
tetramer. Analysis of CCR7 and CD45RA surface expression was performed 
after gating on the PR1/HLA-A2 dextramer-positive cell population (i.e., PR1-
CTL). Cells were classified based on the following staining pattern: central 
memory (CCR7+/CD45RA-), effector memory (CCR7-/CD45RA-), naïve 
(CCR7+/CD45RA+) or terminally differentiated (CCR7-/CD45RA+).  
  
UPN 4 UPN 8 








Table 3. PR1-CTL frequency in HLA-A2+ multiple myeloma patients 
following autologous stem cell transplantation. 
 
Patient MM subtype Days post auto-SCT Alive status 
% PR1 tetramer 
staining 
UPN21 IgG kappa 98 Yes 0.24 
UPN22 IgG kappa 154 Yes 0.22 
UPN23 IgG kappa 170 Yes 0.29 
UPN24 IgG kappa 260 Yes 0.25 
UPN25 IgG kappa 1895 Yes 0.12 
UPN26 IgG kappa 32 Yes 0.21 
UPN27 IgA kappa 454 Yes 0.081 
UPN28 IgG kappa 36 Yes 0.12 
UPN29 IgG lambda 962 Yes 0.098 
UPN30 Lambda light chain 104 Yes 0.076 
UPN31 Kappa light chain 392 Yes 1.31 
UPN32 IgG lambda 353 Yes 0.28 
UPN33 IgG lambda 367 Yes 0.4 
UPN34 IgG kappa 301 Yes 0.12 
UPN35 IgA kappa 274 Yes 0.13 
UPN36 IgG kappa 375 Yes 0.16 
UPN37 IgG kappa 351 Yes 0.2 
UPN38 IgG kappa 304 Yes 0.48 
 
Abbreviations: UPN, unique patient number; MM, multiple myeloma; auto-SCT, 




Figure 30. Gating Strategy used to determine PR1-CTL frequency in 
peripheral blood of multiple myeloma patients following autologous stem 




Figure 30. Gating Strategy used to determine PR1-CTL frequency in 
peripheral blood of multiple myeloma patients following autologous stem 
cell transplantation. Cells were stained with CD3, CD8 and PR1/HLA-A2-
tetramer and the lineage (Lin) markers CD4, CD14, CD16 and CD19. The 
frequency of PR1/HLA-A2 tetramer+ cells (i.e. PR1-CTL) was determined as the 































Lastly, we used flow cytometry to study the expression of PR1 on CD138+ 
multiple myeloma cells from patient bone marrow (to corroborate confocal 
microscopy data [Table 1; Figure 25]) and to also investigate the expression of 
co-stimulatory molecules on PR1/CD138+ multiple myeloma cells.  Our data 
show surface expression of PR1 and co-stimulatory molecules HLA-DR, CD40, 
CD80 and CD86 on CD138+ multiple myeloma cells in 12 out of 12 total patients 
(Table 4; Figure 31), further supporting the observation that patient multiple 




Table 4. Co-stimulatory molecule expression of PR1/HLA-A2+ multiple 
myeloma patients. 
  












































































































































Table 4. Co-stimulatory molecule expression of PR1/HLA-A2+ multiple 
myeloma patients. 
Abbreviations: UPN, unique patient number; MFI, median fluorescence intensity; 
N/A, not applicable. H2023 lung cancer, T-47D breast cancer, MDA-BM-453 
breast cancer cell lines used as negative controls. 
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Figure 31. Gating Strategy used to determine PR1 expression and co-























Figure 31. Gating Strategy used to determine PR1 expression and co-
stimulatory molecule expression on patient bone marrow multiple myeloma 
cells. Cells were stained with CD19, CD33, CD34, CD38, CD138, and HLA-
A2/PR1 antibody (8F4) to identify PR1 expressing multiple myeloma cells. 
Analysis of surface expression for CD40, CD80, CD86, and HLA-DR was 




5.5 Chapter 5 Summary 
 
This work illustrates that cross-presented antigens can be effectively 
targeted using immunotherapy in the setting of multiple myeloma. We have 
demonstrated that multiple myeloma can cross-present PR1, and consequently 
be targeted using PR1-targeting immunotherapy using PR1-CTL and the 8F4 
antibody in vitro and in vivo. Utilizing in vitro cytotoxicity assays, U266 were 
eliminated after being cultured in media supplemented with soluble NE or P3 by 
PR1-CTL and 8F4 antibody. Additionally, we utilized a multiple myeloma 
xenograft mouse model, which illustrated that PR1-CTL and 8F4 antibody 
treatment can drastically reduce the multiple myeloma burden in mice and extend 
animal survival.  
  
 Additionally, we observed the presence of PR1-CTL in the peripheral 
blood and bone marrow of multiple myeloma patients. PR1-CTL were detected in 
the peripheral blood of patients after allo- and auto-SCT and were primarily 
observed to be effector memory cells. Collectively, this suggests that there is the 
potential to elicit immunity against PR1 in multiple myeloma patients. Our data 
also indicate that PR1-expressing multiple myeloma cells from patients express 
the co-stimulatory molecules HLA-DR, CD40, CD80, and CD86. This finding 
suggests that multiple myeloma cells could be capable of cross-priming, a 
potential ancestral role from their B cell origin. 
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 Overall our work has illustrated that cross-presentation of PR1 renders 
multiple myeloma susceptible to PR1-targeting immunotherapies. 
  
 102 
Chapter 6: Discussion 
 
In summary, our work demonstrates the novel ability for multiple myeloma 
cells to take up and cross-present NE and P3. Multiple myeloma cells lack 
endogenous NE and P3 expression but possess the ability to internalize these 
proteins from soluble or cell-associated sources. This internalization leads to the 
processing of NE and P3 by the proteasome and the subsequent loading of PR1 
peptide onto HLA-A2 molecules in a TAP-dependent manner.  This process 
ultimately results in PR1/HLA-A2 expression by multiple myeloma through cross-
presentation. Consequently, PR1 cross-presentation leads to the ability to target 
and eliminate multiple myeloma cells by PR1-targeting immunotherapies such as 
PR1-CTL or 8F4 antibody (Figure 32). Overall, our work has identified cross-
presentation as a novel mechanism by which multiple myeloma expresses tumor 
antigens and underlines the therapeutic potential of PR1-targeting 
immunotherapies for the treatment of multiple myeloma. This suggests that the 
antigen landscape in myeloma is broader than previously believed. This newly 
appreciated and expanded antigen repertoire may lead to the discovery of a new 
class of multiple myeloma antigens and the development of new 
immunotherapies.  
 
 The antigenic library of multiple myeloma is rapidly expanding. As briefly 
mentioned in the introduction of this dissertation, there have been several recent 
and promising antigens being investigated for the targeting multiple myeloma 
(CD38, SLAMF7, BCMA). New approaches using immunoprecipitation and mass 
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spectrometry are further expanding the potential antigenic profile of multiple 
myeloma.71 However, these endeavors have focused primarily on endogenous 
peptides and to date have not considered cross-presented peptides as potential 
immunotherapeutic targets. Our work further expands the potential antigenic 
repertoire of multiple myeloma, illustrated by the ability to target a cross-
presented myeloid leukemia antigen, PR1.  
 
 Cross-presentation is an important link between the innate and adaptive 
immune response. Defects in cross-presentation results in the inability to mount 
a proper CD8+ T cell response against exogenous antigens from viral or tumor 
sources.72,73 Classically, B cells are considered to have cross-presentation 
capabilities; being able to cross-present antigens and prime CD8+ T cells.74,75 
Additionally, plasma cells have also been implicated in priming T cells via cross-
presentation.76 Our work here is the first to reveal that multiple myeloma is 
capable of antigen cross-presentation. Interestingly, studies have shown CD38+ 
plasma cells in multiple myeloma patients expressed a range of co-stimulatory 
molecules (CD40, CD80, CD86, HLA-DR), although at low levels.76,77 In one 
specific study, Pérez-Andrés and colleagues observed a progressive decrease in 
the co-stimulatory capacity in malignant plasma cells from MGUS to multiple 
myeloma.77 These observations are corroborated by our own data, which show a 
small subset of multiple myeloma cells express these co-stimulatory molecules 
on the cell surface.  Together, these data suggest that there may exist 
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immunological scenarios where multiple myeloma could function as an APC and 
prime a CD8+ T cell response.  
 
The proteasome plays a prominent role in both antigen presentation and 
cross-presentation. Our work highlights the importance of the proteasome in PR1 
cross-presentation by multiple myeloma. When multiple myeloma cells were 
treated with the proteasome inhibitors, lactacystin or bortezomib, a significant 
reduction in cross-presentation of NE and P3 was observed, noted by the 
decrease in PR1/HLA-A2 surface expression. The role of the proteasome in 
cross-presentation by multiple myeloma is particularly important in the context of 
bortezomib; a front line therapy administered to newly diagnosed myeloma 
patients.  
 
Currently, the precise effects of bortezomib and proteasome inhibition on 
multiple myeloma have yet to be fully elucidated. In our investigations, treating 
multiple myeloma cells with bortezomib in vitro resulted in decreased PR1 cross-
presentation and global HLA-A2 surface expression. However, others have 
shown that following bortezomib treatment, an increase in antigen presentation 
was observed.78,79 Proteins can be processed by various mechanisms, 
specifically through cytoplasmic or lysosomal peptidases, bypassing the 
proteasome. Potentially NE and P3 could also be processed by these peptidases 
or loaded through the alternative vacuolar pathway, leading to PR1 cross-
presentation even in the context of proteasome inhibition. Our own findings have 
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also challenged the idea that proteasome inhibition is damaging to antigen 
presentation. Our in vivo studies, where combination 8F4 antibody and 
bortezomib were administered to U266 xenograft mice resulted in a more potent 
anti-myeloma effect by extending animal survival in the U266 xenograft model. 
Furthermore, when we investigated this cooperative anti-myeloma effect in vitro 
using flow cytometry based apoptosis assays, we also observed increased cell 
death when both drugs were used in combination. Since this contradicts our data 
showing that proteasome inhibition decrease PR1/HLA-A2 expression on the cell 
surface in vitro, we hypothesize that bortezomib could be suppressing global 
antigen presentation in multiple myeloma, potentially reducing the background 
peptide noise on the myeloma cell surface. This could allow for an enrichment of 
PR1/HLA-A2 expression for targeting by 8F4 antibody. Also, the enhanced killing 
of multiple myeloma by the combination of 8F4 and bortezomib may be due to 
mechanisms unique to 8F4, whereby proteasome inhibition could potentiate the 
direct mechanism of action of 8F4; this work is currently being investigated by 
our group.  
 
The proteasome is inherently complex. Studies have even reported that 
peptide generation via proteasome degradation to be mostly a stochastic 
process. In vitro experiments on the SIINFEKL peptide, derived from ovalbumin, 
demonstrated that the proteasome cleaves through this peptide 90% of the 
time.80 This indicates that the proteasome is generally more destructive to 
peptides than productive. Therefore it could be possible that the low 
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concentration of bortezomib may reduce the probability of PR1 peptide 
destruction in the cells that end up presenting PR1. However, these hypotheses 
would need to be further validated through experimentation. It is clear that a 
greater understanding of the effects of proteasome inhibition on cross-
presentation are needed. Specifically, further studies into the mechanistic activity 
of both 8F4 antibody and bortezomib are necessary and warranted, especially in 
the area of multiple myeloma where combination therapy is commonplace.  
 
The other class of anti-myeloma drugs, IMiDs, does not appear to have 
any adverse effects on antigen presentation. Our work demonstrated that 
lenalidomide did not affect the expression of HLA-A2 nor PR1/HLA-A2 
expression on the surface of multiple myeloma. While more consideration is 
needed when potentially combining PR1-targeting immunotherapy with standard 
of care therapies such as bortezomib, PR1 immunotherapies may be more 
readily integrated and combined with IMiDs.   
 
The ER appears to be the major site for PR1 loading onto HLA-A2 in 
multiple myeloma. When treated with an ER to Golgi transport inhibitor, brefeldin 
A, we observed a significant decrease in PR1/HLA-A2 surface expression on 
multiple myeloma cells. This suggests that PR1 cross-presentation follows the 
cytosolic pathway model for cross-presentation. Our work has also demonstrated 
that TAP plays a prominent role in PR1 cross-presentation, as silencing TAP 
resulted in decreased recognition of PR1/HLA-A2 by PR1-CTLs. These 
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observations further support that PR1 cross-presentation follows the cytosolic 
pathway model. However, we have not conducted the experiments to definitively 
rule out the roles of the vacuolar or peptide-exchange models in PR1 cross-
presentation. It is possible that PR1 can be cross-presented via all three 
mechanisms at some level of efficiency-a consideration that could aid in 
explaining the contradictory effects observed with bortezomib proteasome 
inhibition. Others have reported mechanisms in DCs where the HLA-A2 restricted 
peptide, gp100, is efficiently cross-presented via the vacuolar pathway in a TAP-
independent manner.81 Interestingly, it was further demonstrated that the 
vacuolar pathway for cross-presentation is not exclusively TAP-independent.82 
While our data illustrate that the cytosolic pathway and the ER and TAP play a 
prominent role in the cross-presentation of PR1 by multiple myeloma, it is 
becoming clear that the models of cross-presentation are not mutually exclusive. 
Cells may utilize a combination or multiple pathways for effective antigen cross-
presentation.   
 
Interestingly, our PR1 tetramer findings demonstrate that the TCR 
repertoire of multiple myeloma patients contains TCRs that recognize PR1 after 
allo- and auto-SCT. These data further support the feasibility of targeting PR1 in 
multiple myeloma as there appears to be immunity against PR1 in these patients. 
The frequency of PR1-CTL in multiple patients also suggests alternative avenues 
for PR1-based immunotherapies. Natural PR1 immunity could potentially be 
boosted further using PR1 peptide vaccines. In this study, we found PR1-CTL in 
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the peripheral blood and bone marrow, suggesting that these PR1-CTL have the 
capacity to infiltrate and home to the bone marrow tumor site. In agreement with 
these observations, we also noted that the majority of PR1 dextramer positive T 
cells aligned with the effector memory phenotype (CCR7-/CD45RA-). However, 
the fate of these PR1-CTL remains unknown. Further experiments are needed to 
assess their expansion potential and reactivity functions.  Effector memory T 
cells are characterized by their activation status, containing large quantities of 
perforin and IFN-γ, and being poised to readily initiate effector functions upon 
antigenic stimulation.83 It is tempting to speculate that the PR1-CTL we observed 
could function as PR1 marrow-infiltrating lymphocytes (MILs) and could further 
be expanded ex vivo and transferred using adoptive T cell therapy. Although, it is 
important to note that adoptive T cell transfer of naïve or central memory T cell 
subsets may be more ideal for a long-term anti-myeloma immunity.84  
 
While our studies have demonstrated the feasibility of targeting PR1 in 
multiple myeloma, it is important to recognize potential toxicity concerns. We 
recognize that since PR1 is a self-antigen, there may be off target effects when 
utilizing PR1-targeting immunotherapies. PMN and other non-malignant myeloid 
cells endogenously express NE and P3 and would therefore theoretically express 
PR1/HLA-A2 through normal antigen presentation. However, the level of 
expression of PR1 by myeloid precursor cells in the bone marrow was shown to 
be lower than the aberrant expression by leukemia.50 This would suggest a lower 
density of 8F4 on healthy hematopoietic cells that may be insufficient to trigger 
lysis of normal cells. Additionally, extensive preclinical studies and clinical trials in 
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the setting of leukemia have illustrated safety and efficacy of PR1-targeting 
immunotherapies despite PR1 originating from the normal self antigens NE and 
P3.49,50,52,68  
 
Additionally, the safety of targeting self-antigens such as PR1, have been 
supported by the ability to target other tumor-associated self antigens, such as 
Wilm’s Tumor-1 (WT1) and NY-ESO185,86 Similar to PR1, WT1 has HLA-A2 
restricted epitopes and is aberrantly expressed in many solid tumor and 
hematological malignancies, including AML.87 Importantly, WT1 has been 
effectively targeted in AML using WT1-specific immunotherapies, including WT1 
TCR-like monoclonal antibody, WT1 CAR-T cells, and WT1 peptide vaccine, 
without off target toxicities.68,86,88-90 NY-ESO1 is another tumor-associated 
antigen that has been characterized as an attractive immunotherapeutic target in 
multiple myeloma. Despite its origins as a self-antigen, there has been interest in 
developing NY-ESO1 immunotherapies, with success.91 The feasibility of 
targeting other self-antigens indicates that targeting PR1 in multiple myeloma 
may also be a practical strategy.  
 
NE and P3 are primarily localized to the azurophilic granules in mature 
granulocytes and PMN,92 sequestering them from endogenous antigen 
presentation by the cell. Due to this siloing, the majority of NE and P3 are not 
accessible for proteasomal degradation and subsequent antigen processing of 
the PR1 peptide.50 Moreover, transcription of NE and P3 are reduced in pro-
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myelocytes and decreases over granulocyte maturation.93,94 This spatial and 
temporal control over NE and P3 expression may result in low endogenous 
antigen presentation of PR1 by mature granulocytes, which would reduce on-
target off-tumor binding of PR1-targeting immunotherapies. Importantly, targeting 
PR1 has demonstrated clinical safety in the setting of leukemia. Qazilbash and 
colleagues conducted a phase I/II clinical trial that not only demonstrated 
tolerability and safety of PR1 peptide vaccine, but also showed vaccination 
induced specific immunity that correlated with clinical response.49 
 
It is not surprising that we noted some level of binding of 8F4 antibody to 
HLA-A2 molecules alone. This observation is due to the fact that HLA-A2 is part 
of the combined conformational PR1/HLA-A2 epitope that 8F4 antibody 
recognizes. We have observed low background binding in the setting of leukemia 
and lung cancer.40,41,43 Additionally, we did observe very low levels of 
background binding in unpulsed U266 multiple myeloma (Figure 26). In previous 
work from our group, fine epitope mapping revealed that 8F4 antibody has 
contact residues with the helical domain of HLA-A2 molecules, which may help 
provide an explanation for the observed background binding by 8F4 antibody. 
However, binding experiments using ELISA with other high affinity HLA-A2 
peptides (pp65 and WT1) wherein 8F4 antibody failed to recognize these other 




Overall we have described a novel mechanism by which multiple myeloma 
can express new tumor antigens by cross-presentation. These findings will allow 
for new immunotherapies to be applied to treating this malignancy. 
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Figure 32: Summary of PR1 cross-presentation by multiple myeloma. In the 
bone marrow, multiple myeloma cells take up NE and P3 from resident 
polymorphonuclear cells (PMN). NE and P3 are then processed by the 
proteasome and the PR1 peptide is loaded onto HLA-A2 molecules in a TAP-
dependent manner in the ER.  PR1/HLA-A2 complexes are then expressed on 
the multiple myeloma cell surface, rendering multiple myeloma susceptible to 
PR1-targeting immunotherapies such as 8F4 antibody and PR1-CTL.  
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Chapter 7: Future Directions 
 
Our study has provided evidence that multiple myeloma is capable of taking 
up exogenous antigens and cross-presenting novel peptides that can be targeted 
by immunotherapy. However, this raises several new questions to be explored. 
What is the mechanism by which NE and P3 are taken up by multiple myeloma? 
What clinical impact does cross-presentation hold for future treatment of multiple 
myeloma? 
 
The mechanism of NE and P3 uptake in hematological malignancies remains 
an important question. This is due in large part to the ubiquitous expression of 
NE and P3 in inflamed tissues, including tumors. While our group has led the 
investigation into the mechanism of NE uptake in solid tumors, we have yet to 
explore this mechanism in multiple myeloma. Kerros and colleagues have 
delineated a receptor-mediated mechanism for NE uptake in breast cancer. Their 
studies, utilizing immunoprecipitation and mass spectrometry, identified that 
neuropilin-1 (NRP1) is a receptor that is responsible for NE uptake in breast 
cancer.44 Their hypotheses were guided by two important observations. NE 
uptake by breast cancer was observed to be dose and time dependent and was 
saturable after long co-cultures. Additionally, NE was observed to localize to the 
early endosomal compartment at early time points, all of which suggested a 
receptor-mediated mechanism.53 Interestingly, our multiple myeloma uptake 
studies closely resemble the uptake kinetics seen breast cancer cells, suggesting 
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that there may be a receptor responsible for NE uptake by multiple myeloma. 
However, NRP1 expression is notably absent in U266 multiple myeloma cells 
indicating there may be another receptor present and responsible. Similar 
immunoprecipitation and mass spectrometry based approaches could be 
employed to identify the receptor responsible for NE uptake in multiple myeloma. 
These findings would be important in furthering our understanding of antigen- 
and cross-presentation by cancer cells, specifically in the setting of multiple 
myeloma. The mechanism of P3 uptake has yet to fully explored in solid or 
hematological cancers but would be another area of interesting research. 
 
The antigen presentation machinery were shown to play a critical role in PR1 
cross-presentation by multiple myeloma. We specifically investigated the 
essential contributions of the ER/Golgi, proteasome, and TAP. Our work also 
illuminated a potentially integral role of calnexin for HLA maturation in multiple 
myeloma patients. We observed that a lower isoform of calnexin is expressed in 
multiple myeloma patient cells and was correlated to reduced expression of HLA. 
The reduced HLA expression was also observed to resemble the immature, 
double-band, phenotype of HLA molecules that were retained in the ER.66 We 
speculate that the lower calnexin isoform may function as a dominant negative 
chaperone, outcompeting canonical calnexin, and preventing proper HLA folding 
and binding to the PLC. This could be possible as there are three described 
isoforms of calnexin that are produced through alternative mRNA splicing, as 
notated in the UniProt protein database. The shortest variant of calnexin, isoform 
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3, is missing amino acids 1-108 at the N-terminus. This truncation in isoform 3 
could potentially affect the binding of calnexin to HLA through its globular, 
glycan-binding domain, which is formed in part by the N-terminus.95 Additionally, 
canonical length calnexin has been shown to retain HLA in the ER in TAP-
deficient cells.96,97 Together with our studies, these observations suggest a 
possible mechanism of calnexin mediated HLA retention in the ER and improper 
HLA expression. However, more experimentation would be necessary to 
characterize this mechanism and test these hypotheses. Future investigations 
that explore the role of calnexin would be warranted, as from a teleological 
perspective, this could be novel immune escape mechanism utilized by multiple 
myeloma to further avoid CD8+ T cell detection and destruction. 
 
The work presented here illustrates strong preclinical evidence for PR1 
targeting immunotherapies for the treatment of multiple myeloma. Our 
investigations specifically have shown that PR1-CTL and 8F4 antibody can 
effectively reduce the myeloma burden and prolongs survival in xenograft animal 
models.  Additionally, our data highlights that 8F4 antibody therapy could be 
combined with other standard of care treatments already used for treating 
multiple myeloma patients such as lenalidomide and even possibly bortezomib. 
However, further mechanistic studies are necessary to explore how these 
combinatorial therapies may interact. Multiple myeloma patients commonly 
receive granulocyte colony stimulating factor (G-CSF) to mobilize bone marrow 
cells in preparation for auto-SCT. This process increases the expression of NE 
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and P3 in the bone marrow and would therefore increase the availability of 
sources for PR1 for cross-presentation.48,98 8F4 antibody could be readily 
integrated at this stage, as a purging strategy, where multiple myeloma cells 
would be most likely to cross-present PR1. 8F4 would also be highly applicable 
to multiple myeloma patients with large disease burdens. Our pre-clinical studies 
in mice where high disease burdens were significantly reduced with 8F4 antibody 
therapy alone support these speculations. In addition to 8F4 antibody, PR1 has 
been targeted using other modalities such as PR1 peptide vaccine and PR1-CAR 
T cell therapy.49,55 Each of these different strategies could be applied to multiple 
myeloma patients in different stages depending on the disease burden. For 
example, PR1 peptide vaccine could be highly valuable as a consolidation 
therapy post SCT or in the setting of collecting stem cells for transplant. 
Additionally, CAR T cell therapy may find attractive synergy when combined with 
checkpoint blockage.  
 
Finally, to our knowledge, our work is the first to document that multiple 
myeloma can cross-present an exogenous antigen, PR1, and can be targeted for 
destruction using PR1-specific immunotherapies. This important finding opens up 
a new realm of possible exogenous tumor associated antigens to be targeted in 
multiple myeloma. Currently, the exploration for new cancer antigens, via 
surveying the HLA ligandome, has erupted in the field of cancer medicine.71,99-101 
However, our studies suggest that future antigen discovery experiments should 
be conducted with cross-presentation in mind. Importantly, multiple myeloma has 
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a low mutational burden compared to many of cancers.102 Considering that much 
of antigen discovery has focused on neoantigens derived from mutated antigens 
in both solid and hematological cancers, cross-presented peptides may be even 
of higher importance in the setting of multiple myeloma where neoantigens may 
not be as abundant as they are in other cancers. With personalized, individual-
based therapy approaches becoming more of a reality,103,104 it will be even more 
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